Is There A Role of Glycated Hemoglobin for Predicting Major Ad- verse Cardiac Event in ST-Elevation Myocardial Infarction? by Abusari, Muhammad et al.
Is There A Role of Glycated Hemoglobin for Predicting Major Ad-
verse Cardiac Event in ST-Elevation Myocardial Infarction?
Muhammad Abusari1,2*, Cholid Tri Tjahjono3, Dadang Hendrawan3, Yoga Waranugraha3, 
Ayu Asri Devi Adityawati3, Ratna Pancasari2   
1Department of Cardiology and Vascular Medicine, Dr. Soedono General Hospital, Madiun, Indonesia.
2Brawijaya Cardiovascular Research Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
3Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
*Corresponding author at: Brawijaya Cardiovascular Research Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine,
Universitas Brawijaya, Malang, Indonesia
E-mail address: emailnya_aboe@yahoo.com (M. Abusari).
Heart Science Journal
Contents list available at www.heartscience.ub.ac.id
Heart Sci J 2020; 1(3): 15-20
Journal Homepage : www.heartscience.ub.ac.id
A R T I C L E I N F O A B S T R A C T
1. Introduction
Background : Coronary Artery Disease (CAD) especially ST-Elevation Myocardial Infarction (STEMI) is the 
leading cause of mortality worldwide. Hyperglycemia and diabetes mellitus are both prevalent among patients 
with STEMI admitted to the hospital. Glycated hemoglobin (HbA1c) is a marker of glucose control. 
Objectives : We aimed to investigate the role of HbA1c as the predictor of major adverse cardiovascular events in 
STEMI patients. 
Methods : This was a retrospective cohort study. STEMI patients visiting Saiful Anwar General Hospital were 
registered. Patients were divided into three groups based on the HbA1c level <6.5%; 6.5-8.4% and ≥8.5%; 
respectively. The primary endpoint was in-hospital Major Adverse Cardiovascular Events (MACE), including 
cardiac death, recurrent myocardial infarction (MI), recurrent revascularization, acute pulmonary edema, 
cardiogenic shock, malignant arrhythmia, and stroke.
Results: A total of 118 STEMI patients were included in this study, with distribution of 61 patients with HbA1c 
<6.5%, 25 patients with HbA1c 6.5-8.4%, and 31 patients with HbA1c ≥8.5%; respectively. The HbA1C level 
was associated with the history of diabetes mellitus (3.2% vs 36% vs 71%; p =0.000) and random blood glucose 
level at hospital admission (140.71 ± 39.67 mg/dL vs 172.96 ± 53.43 mg/dL vs 366.61 ± 169.67 mg/dL; p = 
0.000). The MACE among three groups was not significantly different (17.7% vs 20% vs 35.5%; p=0,149). 
Conclusion: Our study reveals that the HbA1c level at hospital admission is associated with the history of diabetes 
mellitus and random blood glucose at hospital admission. However, HbA1c could not predict MACE in STEMI 
patients
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 In the past decades, rapid and sustained increase of 
prevalence of cardiovascular disease (CVD),1 leads to a tremendous 
disease burden around the world. Acute coronary syndrome (ACS), 
which consist of Unstable Angina (UA), STEMI, and non-STEMI, is 
responsible for almost half of the CVD-associated morbidity.2 STEMI is 
associated with acute total occlusion of the coronary arteries. It is the 
most high-risk emergency condition and still be the highest cause of 
mortality and morbidity. Revascularization strategy, including primary 
percutaneous coronary intervention (PPCI) and thrombolysis, must be 
performed to open acute total occlusion in the culprit artery and ensure 
adequate myocardial perfusion to prevent further myocardial damage.3 
The mortality in STEMI patients can be affected by several factors, such 
as the history of previous MI, Killip class, advanced age, emergency 
medical system (EMS)-based STEMI networks presence, time delay to 
treatment, treatment strategy, left ventricular ejection fraction (LVEF), 
number of diseased coronary arteries, diabetes mellitus, and renal 
failure.3,4 
 Diabetes mellitus is a systemic metabolic disease that causes 
complications in microvascular (retinopathy, neuropathy, and 
nephropathy) and macrovascular (coronary artery disease, cerebrovas-
cular disease, and peripheral artery disease,).5 Adequate glycemic 
control, defined as HbA1c value ≤ 7% has an essential role in prevent-
ing those dreadful complications.6 HbA1c reflects the mean glycemia 
level over the previous 8 to 12 weeks period.7 HbA1c levels also have a 
prognostic value for the onset of CVD in the future.8 However, the role 
of the HbA1c level in predicting the outcome of ACS is still unclear and 
needs to be proven. Several reports have shown that in patients with 
15
Original Article
               
    
      
https://doi.org/10.21776/ub.hsj.2020.001.03.4
Received 9 September 2020; Received in revised form 12 September 2020; Accepted 24 September 2020
Available online 21 October 2020
2721-9976 / ©UB Press. All rights reserved.
M. Abusari, et al. Heart Sci J 2020; 1(3): 15-20
STEMI, the HbA1c levels have a prognostic value. However, these 
reports data remain inconclusive.9,10 This study is aimed to investigate 
the role of HbA1c as the predictor of MACE in STEMI patients. 
2. Methods
2.1. Design
 We conducted a retrospective cohort study in Saiful Anwar 
General Hospital Malang, Indonesia, from May to August 2017. The 
investigation was approved by the institutional review board of Saiful 
Anwar General Hospital and conformed with all the principles outlined 
in the Declaration of Helsinki.  
2.2. Study population
 All STEMI patients from April 2015 to August 2017 were 
registered and included in this retrospective cohort study. The data 
about age, gender, STEMI characteristics, CVD risk factors, past medical 
history, vital signs, laboratory finding, medication, revascularization 
strategy, Killip class, Global Registry of Acute Coronary Events 
(GRACE) risk score, thrombolysis in myocardial infarction (TIMI) risk 
score, and MACE were collected from the medical records. The 
additional information was obtained via a phone call interview. The 
exclusion criteria included (1) incomplete data, (2) chronic kidney 
disease (CKD), and (3) anemia.
2.3. Exposure and Outcome
 The exposure was the HbA1c level at hospital admission. 
HbA1c was obtained from peripheral venous blood samples taken at 
hospital admission. According to the HbA1c level, Patients were divided 
into three groups; <6.5% (group 1); 6.5-8.4% (group 2), ≥8.5% 
(group 3). The outcome measure was in-hospital MACE. MACE was 
defined as the composite of total cardiac death, recurrent MI, recurrent 
revascularization, acute pulmonary edema, cardiogenic shock, 
malignant arrhythmia, and stroke (Figure 1).
Figure 1. Study flowchart
2.4. Statistical Analysis
 Categorical data ware presented as number and its percent-
age. However, the numeric data were presented as mean and its 
standard deviation. Chi-square test was conducted for categorical data 
analysis. For normally distributed data, numeric data was analyzed 
using the analysis of variance (ANOVA) test.However, if the data 
abnormally distributed, the statistical analysis of numerical data was 
conducted using the Kruskal Wallis test. The analysis was conducted 
using IBM SPSS version 22 software.
3. Result
3.1. Baseline Characteristics 
 In this retrospective cohort study, we successfully registered 
188 STEMI patients. However, 70 patients were excluded due to one or 
more the following reasons: (1) incomplete data, (2) chronic kidney 
disease (CKD), or (3) anemia. Finally, a total of 118 STEMI patients 
were involved in the statistical analysis process with distribution: (1) 61 
patients of HbA1c <6.5% (group 1); (2) 25 patients of HbA1c 6.5-8.4% 
(group 2); and (3) 31 patients of HbA1c ≥8.5% (group 3). The study 
flowchart is summarized in Figure 1.
 Overall, baseline characteristic among the three groups were 
not significantly different. However, lower HbA1c level was more 
common in male patients (88.7% vs 80% vs 58.1%; p =0.003) and 
cigarette smokers (77.4% vs 60% vs 51.6%; p = 0.032). HbA1C level 
also associated with previous history of diabetes mellitus (3.2% vs 36% 
vs 71%; p = 0.000), random blood glucose level at admission (140.71 
± 39.67 mg/dL vs 172.96 ± 53.43 mg/dL vs 366.61 ± 169.67 mg/dL; 
p = 0.000), and TIMI risk score (p = 0.037). The mean onset of STEMI 
was ranging from 7.52 to 8.83 hours and not all patients received 
revascularization therapy including PPCI or thrombolysis (Table 1). 
 Overall, medications given during in-hospital treatment were 
similar among the three groups.  dual antiplatelet treatment (aspirin 
and P2Y12ADP inhibitor) and anticoagulant were given to all patients. 
The difference of angiotensin-converting enzyme (ACE) inhibitor, 
angiotensin receptor blocker (ARB), β-blocker, mineralocorticoid 
receptor antagonist (MRA), nitrate, and a statin administration among 
three groups were not significant (p ≥ 0.05). The medication during 
in-hospital treatment is summarized in table 2.
 MACE, including cardiac death, recurrent MI, recurrent 
revascularization, acute pulmonary edema, cardiogenic shock, 
malignant arrhythmia, and stroke was the endpoint of this study. 
Statistically, the MACE among three groups was not significantly 
different (17.7% vs 20% vs 35.5%; p = 0,149). MACE among the three 
groups is shown in figure 2.
16
 
 Figure 2. Major adverse cardiovascular events
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Table 1. Baseline characteristics 
Parameter HbA1c < 6.5% n=62
HbA1c ≥ 8.5%
n=31 
p-Value -
57.74 ± 9.23
55 (88.7)
126.66 ± 34.59
77.24 ± 19.02 
76.40 ± 21.36)
3 (4.8)
48 (77.4)
2 (3.2)
32 (51.6)
10 (16.1)
7 (11.3)
1 (1.6)
0 (0)
2 (3.2)
7.52 ± 7.20
35 (56.5)
12 (19.4)
33 (53.2)
43 (69.4)
3 (4.8)
4 (6.5)
12 (19.4)
13 (21)
46 (74.2)
3 (4.8)
17 (27.4)
25 (40.3)
20 (32.3)
Age
Male
Systolic bloos pressure
Diastolic blood pressure  
Heart Rate
CVD Risk Factors
Family history of sudden death
Cigarette smoking
Diabetes Mellitus
Hypertension
Dyslipidemia 
Past medical history
Heart Failure
Stroke 
COPD
Coronary Artery Disease
STEMI
Onset
Anterior STEMI
Primary PCI
Fibrinolytic
Killip Class
I
II
III
IV
TIMI Risk Score
0-2
3-8
9-14
GRACE Risk Score
≤108
109-140
>140
59.87 ± 10.35
18 (58.1)
 126.13 ±40.40
75.23 ± 26.16
81.10 ± 24.91
3 (9.7)
16 (51.6)
22 (71)
21 (67.7)
4 (12.9)
5 (16.1)
1 (3.2)
0 (0)
2 (6.5)
8.83 ± 7.29
21 (67.7)
6 (19.4)
19 (61.3)
19 (61.3)
0 (0)
2 (6.5)
10 (32.3)
2 (6.5)
24 (77.4)
5 (16.1)
4 (12.9)
13 (41.9)
14 (45.2)
0.359
0.003
0.628
0.319
0.622
0.262
0.032
0.000
0.324
0.109
0.800
0.332
0.156
0.416
0.105
0.058
0.930
0.438
0.489
0.037
0.195
60.88 ± 11.68
20 (80)
 314.12 ± 29.17
83.28 ± 15.46
78.12 ± 18.89 
0 (0)
15 (60)
9 (36)
15 (60)
0 (0)
3 (12)
2 (8)
1 (4)
0 (0)
8.28 ± 8.21
9 (36)
4 (16)
11 (44)
18 (72)
1 (4)
2 (8)
4 (16)
4 (16)
21 (84)
0 (0)
5 (20)
8 (32)
12 (48)
HbA1c < 6.5% - 8.4%
n=25
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Note, data were presented in mean ± SD or n(%); HbA1c = The hemoglobin A1c; CVD = Cardiovascular disease; Aspartate aminotransferase; COPD = Chronic 
obstructive pulmonary disease; STEMI = ST-elevation myocardial infarction; PCI = Percutaneous coronary intervention; TIMI = Thrombolysis in Myocardial 
Infarction; GRACE = The Global Registry of Acute Coronary Events; HDL = high-density lipoproteins; LDL = low-density lipoproteins.
0.317
0.276
0.105
0.000
0.850
0.142
0.900
0.832
Table 2. Medical treatment during in hospital treatment
Parameter HbA1c < 6.5% n=62  p-Value
62 (100)
62 (100)
62 (100)
45 (72.6)
35 (56.5)
59 (95.2)
44 (71)
2 (3.2)
3 (4.8)
Anticoagulant
Aspirin
P2Y12ADP inhibitor
Nitrate
β-blocker
Statin
ACE inhibitor
ARB
Spironolactone
31 (100)
31 (100)
31 (100)
21 (67.7)
12 (38.7)
27 (87.1)
17 (54.8)
2 (6.5)
2 (6.5)
-
1.000
1.000
1.000
0.375
0.193
0.112
0.182
0.608
0.845
Laboratory findings
Hemoglobin
Leucocyte
Creatinine
Random blood sugar
Total cholesterol
Triglyceride
HDL
LDL
514.03 ± 1.29
13045.6 ± 3248.25
1.18 ± 0.48
140.71 ± 39.67
176.53 ± 55.21
143.19 ± 110.88
38.42 ± 15.23
121.34 ± 45.1
14.3 ± 2.36
14476.8 ± 5140.25
0.99 ± 0.4
172.96 ± 53.43 
182.72 ± 41.29
145.8 ± 61.65
38.76 ± 8.03
126.6 ± 32.07
13.64 ± 1.65
13199.35 ± 3661.12
1.31 ± 0.9
366.61 ± 169.67
181.42 ± 55.14
162.32 ± 95.29
37.29 ± 11.77
120 ± 45.71
HbA1c < 6.5% - 8,4%
n=25
HbA1c ≥ 8.5%
n=31
25 (100)
25 (100)
25 (100)
21 (84)
15 (60)
25 (100)
19 (76)
2 (8)
2 (8)
Note, data were presented in mean ± SD or n(%); HbA1c = The hemoglobin A1c; ACE = Angiotensin-converting enzyme; ARB = Angiotensin-receptor blockers. 
4. Discussion
 Since introduced in 1980, HbA1c has become a cornerstone 
of diabetes mellitus diagnostic criteria and treatment goals.11 HbA1c 
reflects total blood glucose exposure to the red blood cells. The 
turnover of HbA1c depends on the red blood cell lifespan; therefore, it 
reflects the average plasma glucose over the previous 8 to 12 
weeks.7,12  HbA1C level can be measured at any time. It does not need 
any specific preparation, such as fasting at least 8 hours before the 
blood sample is taken.13 In this study, lower HbA1c level more common 
in male patient (88.7% vs 80% vs 58.1%; p =0.003). Our result did not 
support a previous study by Qinglin et al., which involved 18,265 
patients. They revealed that in the general population, the HbA1c levels 
were influenced by sex and age. The HbA1c level in men was slightly 
higher than in women, and with increasing age, the levels 
would also increase gradually.14 The possible explanations for this 
discrepancy were: (1) only STEMI patients were included, not the 
general population; and (2) smaller sample size. 
 This study found that the higher TIMI value was found in the 
group with higher HbA1c. It was because the TIMI value also contained 
components of (1) age; (2) Killip class; (3) anterior MI or left bundle 
branch block (LBBB); (4) systolic blood pressure; (5) heart rate; (6) 
weight; (7) prior angina; (8) diabetes mellitus; (9) hypertension, and 
(10) time to thrombolytic.15 Therefore, higher levels of HbA1c were 
found to be correlated with high TIMI value.   
 In this study, the history of diabetes mellitus was associated 
with increased levels of HbA1c at admission due to STEMI. A study by 
Timmer et al.obtained a similar result that patients admitted because 
V. Kurniawati, et al. Heart Sci J 2020; 1(2): 11-18
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of ACS and high HbA1c levels were found in patients with a previous 
history of diabetes mellitus. Blood glucose level control is essential in 
diabetic patients. Poor glucose control before the onset of STEMI, as 
illustrated by high levels of HbA1c at admission, can cause many 
complications in diabetic patients.16 Pusuroglu et al. showed poor 
glucose control, as reflected by increased HbA1c levels, increased 
mortality, reinfarction, and stroke in diabetes mellitus patients in 
long-term monitoring.17 A long-term study from Hwang et al. revealed 
that tight blood glucose level control assessed using controlled HbA1c 
levels could reduce mortality, MI, and stroke.18
 In this study, we found a close relationship between an 
increase in blood glucose and HbA1c levels. Hyperglycemia at hospital 
admission is a common comorbid in STEMI.19 This condition can occur 
in patients with diabetes mellitus and patients with a history of diabetes 
mellitus. The prevalence of diabetes mellitus ranged from 12.4% to 
25% of hyperglycemia patients at hospital admission.20 Hyperglycemia 
on admission is a mortality predictor in MI patients.21 During hypergly-
cemia, the cytokines level is increased, especially tumor necrosis 
factor-alpha (TNFα). These cytokines caused endothelial dysfunction 
and reduced myocardial contractility.22,23 In patients with STEMI who 
are accompanied by hyperglycemia signs, it will be challenging to dig 
about the previous history of DM. In this study, blood glucose levels on 
admission to the hospital were not an independent predictor of mortali-
ty. It may be regarding the comprehensive management of hyperglyce-
mia in STEMI patients, and multifactorial causes of mortality.
 
 This study did not reveal a significant relationship between 
HbA1c levels on admission with clinical outcomes, although there was 
an increased rate of worsening clinical outcomes among three groups 
(17.7% vs. 20% vs. 35.5%; p = 0,149). Other studies by Timmer JR et 
al. and Cakmak et al. revealed that the HbA1c value failed to predict 
in-hospital mortality although data on higher mortality were found, 
after adjusting several cardiovascular risk factors. Therefore, it was 
concluded that HbA1c levels were not a strong predictor of increased 
long-term mortality.16,24 A study, including a large population by 
Optimal Therapy in Myocardial Infarction With Angiotensin II Antago-
nist Losartan (OPTIMAAL), also concludes that HbA1c levels were not a 
predictor of mortality in patients with diabetes mellitus.25
 
 Our study had several limitations. First, the data in this study 
were obtained from the medical record, which may cause errors in 
recording. Second, data were obtained from a single-center; therefore, 
they could not represent the overall population. Third, our study 
involved a small number of samples. Fourth, we had several confound-
ing factors that could not be managed, for example, revascularization 
strategy. Not all patients included in this study received revasculariza-
tion. Some parameters in the previous studies that were considered to 
be the cause of mortality were not proven to cause mortality in this 
study. The possible explanation was the data obtained only described 
the initial conditions at hospital admission. Some patients also suffered 
from mechanical complications due to STEMI, which may have a more 
significant role in mortality than just the HbA1c level value.  Some 
patients are also on a ventilator due to respiratory failure, which may 
have a more significant role in patient mortality than the initial HbA1c 
value.
4. Discussion
 Our study revealed that the HbA1c level at hospital admis-
sion is associated with the history of diabetes mellitus and random 
blood glucose at hospital admission. However, the HbA1c level at 
hospital admission could not predict MACE in STEMI patients.
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